Back to search

Article

Camrelizumab In Patients With Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Cost-Effective Analysis In China

2021-09-14

Abstract excerpt

<h4>Background: </h4> Camrelizumab is a selective, humanized, high-affinity IgG4 kappa monoclonal antibody against programmed cell death 1 (PD-1) that shows effective antitumor activity with acceptable toxicity in multiple tumor types. The CameL trial demonstrated that camrelizumab plus chemotherapy significantly prolonged the median progression-free survival (PFS) and median overall survival (OS) versus chemother...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
b524fcf7-3816-5bd8-9372-3fb3515ca55a
DOI
10.21203/rs.3.rs-839456/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Camrelizumab In Patients With Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Cost-Effective Analysis In ChinaDOI 10.21203/rs.3.rs-839456/v1
First-Line Pembrolizumab Plus Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A United States-Based Cost-Effectiveness AnalysisSemantic proximity
First-Line Pembrolizumab Plus Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness AnalysisSemantic proximity
Efficacy and safety of different PD-1 inhibitors as first-line treatment for advanced or metastatic squamous non-small cell lung cancer: A retrospective real-world studySemantic proximity
Efficacy and Safety Analysis of Camrelizumab, Sintilimab, and Tislelizumab in the Treatment of NSCLC in Xuanwei, China: A Retrospective Real-World StudySemantic proximity
Efficacy and safety of immune checkpoint inhibitors versus chemotherapy in advanced non-small cell lung cancer: A systematic review of randomized controlled trialsSemantic proximity
Cost-Effectiveness of Sacituzumab Tirumotecan vs Chemotherapy for EGFR- TKI–Resistant NSCLC: Evidence to Inform Drug Pricing in the U.S. and ChinaSemantic proximity
Cost-effectiveness of Trastuzumab emtansine and Capecitabine plus lapatinib in adjuvant treatment of Human Epidermal Growth Factor Receptor 2– Positive Metastatic Breast Cancer in ChinaSemantic proximity
Cost-effectiveness analysis of sacituzumab tirumotecan as second-line therapy for EGFR-TKI-resistant, EGFR-mutated advanced NSCLC in China.Semantic proximity
Comparative Safety of Immune Checkpoint Inhibitors and Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-AnalysisSemantic proximity
Cost-effectiveness analysis of sacituzumab tirumotecan vs. chemotherapy for patients with EGFR-TKI-resistant, EGFR-mutated advanced non-small cell lung cancer in China.Semantic proximity
The safety and economic evaluation of bevacizumab and PD-1 inhibitors for advanced non- squamous NSCLC: a multicenter observational study in ChinaSemantic proximity
Efficacy and Safety of Immuno-based Therapy Versus Standard of Care in Extensive-stage Small-Cell Lung Cancer: An Updated Meta-analysis of Randomized Clinical TrialsSemantic proximity
Select a neighboring publication to make it the new centre.